公开(公告)号：US20250027960A1

公开(公告)日：2025-01-23

申请号：US18829111

申请日：2024-09-09

Applicant: CLEVELAND HEARTLAB, INC.

Inventor： Timothy Collier ,  Cory Bystrom ,  Angela Higgins

IPC: G01N33/92 ,  C07K14/775 ,  G01N1/34

Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.

公开(公告)号：US20190250177A1

公开(公告)日：2019-08-15

申请号：US16208739

申请日：2018-12-04

Applicant: CLEVELAND HEARTLAB, INC.

Inventor： Timothy Collier ,  Cory Bystrom ,  Angela Higgins

IPC: G01N33/92 ,  C07K14/775 ,  G01N1/34

CPC classification number: G01N33/92 ,  C07K14/775 ,  G01N1/34

Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.

公开(公告)号：US20240310391A1

公开(公告)日：2024-09-19

申请号：US18615987

申请日：2024-03-25

Applicant: CLEVELAND HEARTLAB, INC.

Inventor： Cory Bystrom ,  Timothy COLLIER

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2333/775

Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.

公开(公告)号：US12085577B2

公开(公告)日：2024-09-10

申请号：US17367049

申请日：2021-07-02

Applicant: CLEVELAND HEARTLAB, INC.

Inventor： Timothy Collier ,  Cory Bystrom ,  Angela Higgins

IPC: G01N33/53 ,  C07K14/775 ,  G01N1/34 ,  G01N33/92

CPC classification number: G01N33/92 ,  C07K14/775 ,  G01N1/34

Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.

公开(公告)号：US11940452B2

公开(公告)日：2024-03-26

申请号：US16667016

申请日：2019-10-29

Applicant: CLEVELAND HEARTLAB, INC.

Inventor： Cory Bystrom ,  Timothy Collier

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2333/775

Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.

公开(公告)号：US20210373038A1

公开(公告)日：2021-12-02

申请号：US17367049

申请日：2021-07-02

Applicant: CLEVELAND HEARTLAB, INC.

Inventor： Timothy Collier ,  Cory Bystrom ,  Angela Higgins

IPC: G01N33/92 ,  G01N1/34

Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.

公开(公告)号：US20220155302A1

公开(公告)日：2022-05-19

申请号：US17588925

申请日：2022-01-31

Applicant: CLEVELAND HEARTLAB, INC.

Inventor： Celalettin Topbas ,  Cory Bystrom

IPC: G01N33/573 ,  G01N1/28

Abstract: Provided herein are methods, systems, and compositions for Lp-PLA2 detection assays that employ amounts of detergent to liberate all or nearly all of the Lp-PLA2 molecules from associated lipoprotein particles. In this regard, the true Lp-PLA2 concentration can be detected in a sample, which correlates better with known Lp-PLA2 activity assays.

公开(公告)号：US20210132090A1

公开(公告)日：2021-05-06

申请号：US17143463

申请日：2021-01-07

Applicant: Cleveland Heartlab, Inc.

Inventor： Cory Bystrom ,  Timothy Collier

IPC: G01N33/92

Abstract: Provided herein are methods, systems, and compositions for detecting one or more HDL-associated proteins (e.g., ApoC3; ApoC3 and ApoA1; ApoC3 and SAA1/2; or proteins in Biomarker Panels 1-30) in a sample from a subject with, or suspected of having, cardiovascular disease (CVD) or other HDL related disease. In certain embodiments, such methods, systems, and compositions are used to determine the approximate risk of CVD (or other disease) for a subject, and/or the approximate cholesterol efflux capacity (CEC) of a sample.

公开(公告)号：US20150376704A1

公开(公告)日：2015-12-31

申请号：US14788828

申请日：2015-07-01

Applicant: CLEVELAND HEARTLAB, INC.

Inventor： Doug Harrington ,  Evangelos Hytopoulos ,  Bruce Phelps

IPC: C12Q1/68 ,  G01N33/68 ,  G06F19/00

CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/6893 ,  G01N2570/00 ,  G01N2800/32 ,  G01N2800/50 ,  G01N2800/60 ,  G16B20/00 ,  G16B40/00 ,  G16H50/20

Abstract: The disclosed methods, assays and kits identify biomarkers, particularly miRNA and/or protein biomarkers, for assessing the cardiovascular health of a human. In certain embodiments, methods, assays and kits, circulating miRNA and/or protein biomarkers are identified for assessing the cardiovascular health of a human.

Abstract translation: 所公开的方法，测定和试剂盒鉴定用于评估人的心血管健康的生物标志物，特别是miRNA和/或蛋白质生物标志物。 在某些实施方案中，鉴定了用于评估人的心血管健康的方法，测定和试剂盒，循环的miRNA和/或蛋白质生物标志物。

公开(公告)号：US20150331000A1

公开(公告)日：2015-11-19

申请号：US14713046

申请日：2015-05-15

Applicant: CLEVELAND HEARTLAB, INC.

Inventor： Timothy Collier ,  Cory Bystrom ,  Angela Higgins

IPC: G01N33/92 ,  G01N1/34

CPC classification number: G01N33/92 ,  C07K14/775 ,  G01N1/34

Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.

Abstract translation: 本发明提供了使用包含HDL亲脂性核心结合肽（例如，ApoA1的部分）和亲和标签的HDL标记分子从样品（例如血液样品）中纯化HDL分子的方法，试剂盒和组合物。 本发明还提供用质谱法检测非碎片化的ApoA1的方法，试剂盒和组合物。 本发明还提供用于标记具有可检测标记的ApoA1分子的样品中的HDL分子的方法，试剂盒和组合物，使得可测定可检测标记的ApoA1分子与天然ApoA1蛋白的比例。